Blog
RSS FeedPosted by Michael Wonder on 06 Nov 2020
ICER publishes evidence report on digital therapeutics for opioid use disorder
6 November 2020 - The available evidence on the benefits of reSET-O, Connections, and DynamiCare has substantial limitations and can ...
Posted by Michael Wonder on 02 Nov 2020
ICER Names Leigh Purvis to Governance Board, Mark McClellan to Advisory Board
2 November 2020 - New members’ broad leadership experience — spanning biomedical policymaking and consumer advocacy for ageing populations — will ...
Posted by Michael Wonder on 21 Oct 2020
ICER posts draft scoping document for the assessment of Alzheimer’s disease
21 October 2020 - Document open to public comment until 10 November 2020. ...
Posted by Michael Wonder on 20 Oct 2020
Biden looks to Germany for answers on how to tackle high U.S. drug prices
20 October 2020 - With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues ...
Posted by Michael Wonder on 18 Oct 2020
ICER publishes final report and policy recommendations for targeted immune modulator therapies for ulcerative colitis
16 October 2020 - Independent appraisal committee votes that evidence is adequate to demonstrate clinical superiority of vedolizumab over adalimumab. ...
Posted by Michael Wonder on 17 Oct 2020
ICER publishes evidence report on therapies for haemophilia A
16 October 2020 - Emicizumab assessed as providing comparable or better clinical benefits when compared to common current dosing levels of ...
Posted by Michael Wonder on 10 Oct 2020
In landmark international program, HTA agencies around the world access ICER's customisable COVID-19 cost-effectiveness model
9 October 2020 - Leveraging ICER’s new cloud-based Interactive Modeler platform, Quebec’s HTA agency has used the COVID-19 model to inform ...
Posted by Michael Wonder on 29 Sep 2020
ICER to assess treatment for Alzheimer’s disease
29 September 2020 - Report will be subject of CTAF meeting in May 2021; open Input now being accepted until ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 24 Sep 2020
ICER releases draft evidence report on supervised injection facilities
24 September 2020 - Public comment period now open until 22 October 2020; requests to make oral comment during public ...
Posted by Michael Wonder on 23 Sep 2020
ICER issues final report and policy recommendations on treatments for cystic fibrosis
23 September 2020 - Independent appraisal committee unanimously concludes that Trikafta delivers substantial benefits for patients, family members, and society. ...
Posted by Michael Wonder on 22 Sep 2020
ICER posts draft scoping document on therapies for multiple myeloma
22 September 2020 - Document open to public comment until 13 October 2020. ...
Posted by Michael Wonder on 17 Sep 2020
ICER releases draft evidence reports on bladder cancer and digital therapeutics for opioid use disorder
17 September 2020 - Public comment period now open until 15 October 2020; requests to make oral comment during public meeting ...
Posted by Michael Wonder on 11 Sep 2020
ICER publishes evidence report on targeted immune modulator therapies for ulcerative colitis
11 September 2020 - All assessed therapies provide significant health benefits, but even after rebates, all are priced at levels ...
Posted by Michael Wonder on 31 Aug 2020
ICER posts draft scoping document on lupus nephritis
31 August 2020 - Document open to public comment until 21 September 2020. ...